Cargando…

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas

High proliferation rate and high mutation density are both indicators of poor prognosis in adrenocortical carcinomas. We performed a hypothesis-driven association study between clinical features in adrenocortical carcinomas and the expression levels of 136 genes involved in DNA metabolism and G1/S p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hadjadj, Djihad, Kim, Su-Jung, Denecker, Thomas, Driss, Laura Ben, Cadoret, Jean-Charles, Maric, Chrystelle, Baldacci, Giuseppe, Fauchereau, Fabien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764399/ https://www.ncbi.nlm.nih.gov/pubmed/29283884 http://dx.doi.org/10.18632/aging.101356

Ejemplares similares

Characterization of the replication timing program of 6 human model cell lines
por: Hadjadj, Djihad, et al.
Publicado: (2016)

Efficient, quick and easy-to-use DNA replication timing analysis with START-R suite
por: Hadjadj, Djihad, et al.
Publicado: (2020)

Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner
por: Kim, Su-Jung, et al.
Publicado: (2023)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

KNIME-CDK: Workflow-driven cheminformatics
por: Beisken, Stephan, et al.
Publicado: (2013)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells
por: Chen, T-Y, et al.
Publicado: (2015)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma
por: Liang, Raimunde, et al.
Publicado: (2020)

Identifying Cancers Impacted by CDK8/19
por: Roninson, Igor B., et al.
Publicado: (2019)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Regulatory functions of the Mediator kinases CDK8 and CDK19
por: Fant, Charli B., et al.
Publicado: (2018)

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss
por: Teitz, Tal, et al.
Publicado: (2018)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
por: Wood, Daniel J., et al.
Publicado: (2019)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
por: Dannappel, Marius Volker, et al.
Publicado: (2019)

Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders
por: Zeb, Amir, et al.
Publicado: (2019)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials
por: Kabadi, Shruti V., et al.
Publicado: (2014)

Regulation of CDK4
por: Bockstaele, Laurence, et al.
Publicado: (2006)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Biological functions of CDK5 and potential CDK5 targeted clinical treatments
por: Shupp, Alison, et al.
Publicado: (2017)

Replication Stress, Genomic Instability, and Replication Timing: A Complex Relationship
por: Briu, Lina-Marie, et al.
Publicado: (2021)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
por: Whittaker, Steven R., et al.
Publicado: (2018)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

CDK1 makes the meiotic spindle wait
por: Short, Ben
Publicado: (2013)

CDK5 opens the way for DLC1
por: Short, Ben
Publicado: (2014)

A uniform procedure for the purification of CDK7/CycH/MAT1, CDK8/CycC and CDK9/CycT1
por: Pinhero, Reena, et al.
Publicado: (2004)

MEN1-tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
por: Gillam, Mary P., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jddohiju2r838q2etj8oei7bsh